DNA DAMAGE RESPONSE IN CANCER: GUARDIAN AND TARGET

Mrs.M.Menaka[1*]

[1*]*MSc Nursing OBG, HOD,Obg department, Annai Jkkm sampoorani Ammal college of Nursing, Komarapalaiyam, Namakkal.*

[*]*Corresponding author:*

Abstract

The DNA Damage Response (DDR) is a multifaceted network of cellular pathways responsible for identifying, signaling, and repairing various forms of DNA lesions. Its role in maintaining genomic integrity is essential for cellular homeostasis and the prevention of malignancy. However, cancers often exhibit DDR deficiencies, enabling genomic instability while also creating therapeutic vulnerabilities. This review outlines the central mechanisms of the DDR, its dysregulation in cancer, and the emerging strategies to therapeutically exploit DDR deficiencies in oncology.

1. Introduction

Cells are continuously subjected to genotoxic stress from endogenous sources such as reactive oxygen species and replication errors, as well as exogenous agents including ultraviolet radiation, ionizing radiation, and chemical mutagens. The DNA Damage Response (DDR) is a complex surveillance and repair system that safeguards the genome against these threats (Jackson & Bartek, 2009). When DDR pathways are compromised, cells accumulate mutations that can contribute to carcinogenesis. However, these same defects may be exploited as vulnerabilities in cancer therapy, particularly through synthetic lethality.

2. Core Components of the DNA Damage Response

2.1 Damage Detection

DDR begins with the recognition of DNA lesions. Double-strand breaks (DSBs), one of the most lethal forms of damage, are detected by the MRN complex (MRE11-RAD50-NBS1), which activates the ATM kinase (Stracker & Petrini, 2011). Single-stranded DNA generated during replication stress is recognized by replication protein A (RPA), leading to the recruitment of ATR.

2.2 Signal Transduction

ATM and ATR kinases orchestrate a cascade that activates downstream effectors including CHK1, CHK2, and p53, leading to cell cycle arrest, DNA repair, or apoptosis depending on damage severity (Shiloh, 2003).

2.3 Repair Mechanisms

Key repair pathways include: Base Excision Repair (BER), Nucleotide Excision Repair (NER), Mismatch Repair (MMR), Non-Homologous End Joining (NHEJ), and Homologous Recombination (HR).

3. DDR Deficiency in Cancer

3.1 Oncogenic Mutations and Genomic Instability

Cancer cells frequently harbor mutations in DDR genes, allowing for unchecked proliferation and the accumulation of additional mutations (Hanahan & Weinberg, 2011). For instance: BRCA1/2 mutations impair HR, predisposing individuals to breast and ovarian cancers (Venkitaraman, 2002); TP53 mutations abrogate damage-induced cell cycle arrest; MLH1 silencing in MMR leads to microsatellite instability.

3.2 Tumor Evolution and Therapy Resistance

DDR defects promote intratumoral heterogeneity, fueling tumor evolution and, at times, resistance to therapy (Lord & Ashworth, 2012). Understanding these dynamics is critical for designing effective interventions.

4. Therapeutic Targeting of DDR Deficiencies

4.1 PARP Inhibitors and Synthetic Lethality

PARP inhibitors (e.g., olaparib) exploit HR deficiency by blocking single-strand break repair, causing lethal DSB accumulation in BRCA-mutated cells (Bryant et al., 2005; Farmer et al., 2005).

4.2 Emerging DDR Targets

Inhibitors targeting ATR, CHK1, WEE1, and DNA-PK are under development. These agents aim to selectively kill cancer cells with replication stress or compromised checkpoint function (Yazinski & Zou, 2016).

4.3 DDR and Immunotherapy Synergy

DDR-deficient tumors may generate more neoantigens, increasing susceptibility to immune checkpoint inhibitors. Combining DDR-targeted therapy with immunotherapy is a promising avenue under investigation (Mouw et al., 2017).

5. Challenges and Future Directions

Despite therapeutic promise, several challenges remain: resistance development (e.g., BRCA reversion mutations), identification of predictive biomarkers, and toxicity in normal DDR-compromised tissues. Integrating DDR inhibitors with other modalities and tailoring therapy based on genomic profiling will be key to improving patient outcomes.

6. Conclusion

The DNA Damage Response plays a dual role in cancer as both a barrier to and enabler of tumorigenesis. While its dysfunction promotes malignancy, it also presents actionable vulnerabilities. DDR-targeted therapies, especially in the context of synthetic lethality, offer powerful tools in precision oncology. Ongoing research is expanding the therapeutic arsenal and uncovering new opportunities to exploit DDR deficiencies for clinical benefit.

References

1. Bryant, H. E., et al. (2005). Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature, 434(7035), 913–917.
2. Farmer, H., et al. (2005). Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature, 434(7035), 917–921.

3. Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: The next generation. Cell, 144(5), 646–674. Jackson, S. P., & Bartek, J. (2009). The DNA-damage response in human biology and disease. Nature, 461(7267), 1071–1078.
4. Lord, C. J., & Ashworth, A. (2012). The DNA damage response and cancer therapy. Nature, 481(7381), 287–294.
5. Mouw, K. W., et al. (2017). DNA damage and repair biomarkers of immunotherapy response. Cancer Discovery, 7(7), 675–693.
6. Shiloh, Y. (2003). ATM and related protein kinases: Safeguarding genome integrity. Nature Reviews Cancer, 3(3), 155–168.
7. Stracker, T. H., & Petrini, J. H. (2011). The MRE11 complex: Starting from the ends. Nature Reviews Molecular Cell Biology, 12(2), 90–103.
8. Venkitaraman, A. R. (2002). Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell, 108(2), 171–182.
9. Yazinski, S. A., & Zou, L. (2016). Functions, regulation, and therapeutic implications of the ATR checkpoint pathway. Annual Review of Genetics, 50, 155–173.